Garden Introduces BLOOM for Real-Time IP-Aware AI Drug Design
Garden has launched BLOOM, a Markush structure search engine designed to provide AI drug-design teams with near-instant verification of small-molecule IP landscapes, announced in a press release. This tool allows researchers to iterate on candidates with legal certainty built into the process, addressing the bottleneck of diligence in AI-generated molecule design.
BLOOM employs a graph-based, agentic traversal to compare Markush queries against millions of SMILES strings, effectively short-circuiting invalid candidates through local atom and bond features. The system provides color-coded mapping to confirm atom- and bond-level compliance, transforming verification from a manual task into an automated step.
In benchmark tests, BLOOM demonstrated a 32.44× speed improvement over standard core-extraction string searches, while also reducing false positives that often occur with legacy methods. The engine integrates with Garden's patent database, linking every SMILES match to underlying patent records and supporting workflows from rapid novelty triage to freedom-to-operate analysis.
According to Adi Sidapara, founder and CEO of Garden, BLOOM enables IP-aware exploration without slowing down discovery, ensuring that AI-generated chemistries are checked for existing IP coverage instantly.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
AINGENS Warns AI Tool Fragmentation Complicates Medical Affairs Work
Benchling Launches Science Foundries for Biotech R&D
Bloomberg Law and Regology Debut AI Tools for Corporate Counsel
Phylo Launches Target Atlas for Drug Target Prioritization
Illumina Launches BioInsight Platform for Genomic Research
Daily AI Brief: the AI news that matters, in your inbox.